
The drug, an inhaled powder, completed phase III testing in August of 2013. If approved, it will be the first ultra rapid-acting mealtime insulin therapy available in the United States.
Read more
The drug, an inhaled powder, completed phase III testing in August of 2013. If approved, it will be the first ultra rapid-acting mealtime insulin therapy available in the United States.
Read more